A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States

References

• Schizophrenia and Related Disorders Alliance of America [homepage on the Internet]Schizophrenia and Related Disorders Alliance of America: About Schizophrenia Available from: http://www.sardaa.org/Accessed March 29, 2018
   Google Scholar
• OffordSLinJMirskiDWongBImpact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophreniaAdv Ther201330328628923483449
   PubMed Web of Science ®Google Scholar
• KennedyJLAltarCATaylorDLDegtiarIHornbergerJCThe social and economic burden of treatment-resistant schizophreniaInt Clin Psychopharmacol2014292637623995856
   PubMed Web of Science ®Google Scholar
• KaplanGCasoyJZummoJImpact of long-acting injectable anti-psychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPatient Prefer Adherence201371171118024265549
   PubMed Web of Science ®Google Scholar
• Fuller-ThomsonEHollisterBSchizophrenia and suicide attempts: findings from a representative community-based Canadian sampleSchiz Res Treat20163165243111
   Google Scholar
• KhaykinEEatonWFordDAnthonyCDaumitGHealth insurance coverage among persons with schizophrenia in the United StatesPsy-chiatr Serv2010618830834
   PubMed Web of Science ®Google Scholar
• LangKFedericoVMuserEMenzinJMenzinJRates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophreniaJ Med Econ2013168997100623777223
   PubMedGoogle Scholar
• Centers for Medicare & Medicaid Services [webpage on the Internet]Young Adults and the Affordable Care Act: Protecting Young Adults and Eliminating Burdens on Families and Businesses2010 Available from: https://www.cms.gov/CCIIO/Resources/Files/adult_child_fact_sheet.htmlAccessed May 19, 2017
   Google Scholar
• WuEQBirnbaumHGShiLThe economic burden of schizophrenia in the United States in 2002J Clin Psych20056611221129
   Web of Science ®Google Scholar
• LinJWongBOffordSMirskiDHealthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophreniaJ Behav Health Serv Res201340335536623579871
   PubMed Web of Science ®Google Scholar
• CloutierMSanon AigbogunMGuerinAThe economic burden of schizophrenia in the United States in 2013J Clin Psychiatry201677676477127135986
   PubMed Web of Science ®Google Scholar
• HaynesVSZhuBStaufferVLLong-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational studyBMC Psychiatry201212122223216976
   PubMed Web of Science ®Google Scholar
• CarneyCPJonesLWoolsonRFMedical comorbidity in women and men with schizophrenia: A population-based controlled studyJ Gen Intern Med200621111133113717026726
   PubMed Web of Science ®Google Scholar
• NichollDAkhrasKSDielsJSchadrackJBurden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspectiveCurr Med Res Opin201026494395520163295
   PubMed Web of Science ®Google Scholar
• GibsonTBJingYKimECost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patientsManag Care20101984047
   Google Scholar
• JoshiKLinJLingohr-SmithMFuD-JMuserETreatment patterns and antipsychotic medication adherence among commercially insured patients with schizoaffective disorder in the United StatesJ Clin Psychopharmacol201636542943527525965
   PubMed Web of Science ®Google Scholar
• KimEGuptaSBolgeSChenC-CWhiteheadRBatesJAAdherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional surveyJ Med Econ201013218519220235753
   PubMedGoogle Scholar
• OffordSWongBMirskiDBakerRALinJHealthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oralJ Med Econ201316223123923163287
   PubMedGoogle Scholar
• PyensonBGoldbergSIwasakiKBoyarskyVDiraniRA Medicaid and commercial insured claims-based study to estimate improved antipsychotic medication adherence among patients with schizophreniaJ Behav Health Serv Res201340222223323456182
   PubMed Web of Science ®Google Scholar
• FisherMDReillyKIsenbergKVillaKFAntipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapyBMC Psychiatry20141434125433495
   PubMed Web of Science ®Google Scholar
• WilsonLSGitlinMLightwoodJSchizophrenia costs for newly diagnosed versus previously diagnosed patientsAm J Pharm Benefits201132107115
   Google Scholar
• RostKHsiehYPXuSMenachemiNYoungASPotential disparities in the management of schizophrenia in the United StatesPsychiatr Serv201162661321632729
   PubMed Web of Science ®Google Scholar
• McCombsJZolfaghariSGanapathyVImpact of drug treatment history on comparative effectiveness research in schizophreniaValue Health201114567968621839406
   PubMed Web of Science ®Google Scholar
• PengXAscher-SvanumHFariesDConleyRRSchuhKJDecline in hos-pitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaClin Outcomes Res201131914
   Google Scholar
• DoddsTJPhutaneVHStevensBJWoodsSWSernyakMJSrihariVHWho is paying the price? Loss of health insurance coverage early in psychosisPsychiatr Serv201162887888121807825
   PubMed Web of Science ®Google Scholar
• FitchKIwasakiKVillaKFResource utilization and cost in a commercially insured population with schizophreniaAm Health Drug Benefits201471182624991388
   PubMedGoogle Scholar
• LafeuilleM-HLaliberté-AugerFLefebvrePFroisCFastenauJDuhMSImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisBMC Psychiatry20131322124016390
   PubMed Web of Science ®Google Scholar
• PanishJMDiraniRHalpernRCaoFExploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative databaseJ Med Econ201013461061720879914
   PubMedGoogle Scholar
• StenslandMWatsonPRGrazierKLAn examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitalsPsychiatr Serv201263766667122588167
   PubMed Web of Science ®Google Scholar
• WangCCFarleyJFPatterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel SurveyRes Social Adm Pharm2013926327521272525
   PubMed Web of Science ®Google Scholar
• GianfrancescoFRajagopalanKWangRHospitalization risks in the treatment of schizophreniaJ Clin Psychopharmacol200626440140416855459
   PubMed Web of Science ®Google Scholar
• WilliamsEOStockEMZeberJEPayer types associated with antipsychotic polypharmacy in an ambulatory care settingJ Pharm Health Serv Res201233149155
   Google Scholar
• CitromeLEramoAFrancoisCLack of tolerable treatment options for patients with schizophreniaNeuropsychiatr Dis Treat2015113095310426719694
   PubMed Web of Science ®Google Scholar
• SacchettiEGrunzeHLeuchtSVitaALong-acting injection anti-psychotic medications in the management of schizophreniaEvid Based Psychiatric Care201512736
   Google Scholar
• SeaburySAGoldmanDPKalsekarISheehanJJLaubmeierKLakdawallaDNFormulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in MedicaidAm J Manag Care2014202e52e6024738555
   PubMed Web of Science ®Google Scholar
• LawMRRoss-DegnanDSoumeraiSBEffect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursementsPsychiatric Serv2008595540546
   Web of Science ®Google Scholar
• MancusoASpecchiaMLLovatoEEconomic burden of schizophrenia: the European situation. A scientific literature reviewEur J Public Health201424suppl_235135224642605
   PubMed Web of Science ®Google Scholar